Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Does Lifestyle Intervention After Gastric Bypass Surgery Prevent Weight Regain? A Randomized Clinical Trial.

Hanvold SE, Vinknes KJ, Løken EB, Hjartåker A, Klungsøyr O, Birkeland E, Risstad H, Gulseth HL, Refsum H, Aas AM.

Obes Surg. 2019 Jul 30. doi: 10.1007/s11695-019-04109-7. [Epub ahead of print]

PMID:
31363961
2.

PIK3CA Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma.

Holst F, Werner HMJ, Mjøs S, Hoivik EA, Kusonmano K, Wik E, Berg A, Birkeland E, Gibson WJ, Halle MK, Trovik J, Cherniack AD, Kalland KH, Mills GB, Singer CF, Krakstad C, Beroukhim R, Salvesen HB.

Clin Cancer Res. 2019 Jan 1;25(1):334-345. doi: 10.1158/1078-0432.CCR-18-0452. Epub 2018 Nov 15.

3.

MYC-Induced miR-203b-3p and miR-203a-3p Control Bcl-xL Expression and Paclitaxel Sensitivity in Tumor Cells.

Aakko S, Straume AH, Birkeland EE, Chen P, Qiao X, 'Lønning PE, Kallio MJ.

Transl Oncol. 2019 Jan;12(1):170-179. doi: 10.1016/j.tranon.2018.10.001. Epub 2018 Oct 22.

4.

Patterns of genomic evolution in advanced melanoma.

Birkeland E, Zhang S, Poduval D, Geisler J, Nakken S, Vodak D, Meza-Zepeda LA, Hovig E, Myklebost O, Knappskog S, Lønning PE.

Nat Commun. 2018 Jul 10;9(1):2665. doi: 10.1038/s41467-018-05063-1.

5.

PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer.

Mjos S, Werner HMJ, Birkeland E, Holst F, Berg A, Halle MK, Tangen IL, Kusonmano K, Mauland KK, Oyan AM, Kalland KH, Lewis AE, Mills GB, Krakstad C, Trovik J, Salvesen HB, Hoivik EA.

Sci Rep. 2017 Aug 31;7(1):10240. doi: 10.1038/s41598-017-10717-z.

6.

Expression of Nestin associates with BRCA1 mutations, a basal-like phenotype and aggressive breast cancer.

Krüger K, Wik E, Knutsvik G, Nalwoga H, Klingen TA, Arnes JB, Chen Y, Mannelqvist M, Dimitrakopoulou K, Stefansson IM, Birkeland E, Aas T, Tobin NP, Jonassen I, Bergh J, Foulkes WD, Akslen LA.

Sci Rep. 2017 Apr 24;7(1):1089. doi: 10.1038/s41598-017-00862-w.

7.

Nano-TiO2 penetration of oral mucosa: in vitro analysis using 3D organotypic human buccal mucosa models.

Konstantinova V, Ibrahim M, Lie SA, Birkeland ES, Neppelberg E, Marthinussen MC, Costea DE, Cimpan MR.

J Oral Pathol Med. 2017 Mar;46(3):214-222. doi: 10.1111/jop.12469. Epub 2016 Jul 8.

8.

The MDM4 SNP34091 (rs4245739) C-allele is associated with increased risk of ovarian-but not endometrial cancer.

Gansmo LB, Bjørnslett M, Halle MK, Salvesen HB, Dørum A, Birkeland E, Hveem K, Romundstad P, Vatten L, Lønning PE, Knappskog S.

Tumour Biol. 2016 Aug;37(8):10697-702. doi: 10.1007/s13277-016-4940-2. Epub 2016 Feb 11.

9.

Tumor necrosis is an important hallmark of aggressive endometrial cancer and associates with hypoxia, angiogenesis and inflammation responses.

Bredholt G, Mannelqvist M, Stefansson IM, Birkeland E, Bø TH, Øyan AM, Trovik J, Kalland KH, Jonassen I, Salvesen HB, Wik E, Akslen LA.

Oncotarget. 2015 Nov 24;6(37):39676-91. doi: 10.18632/oncotarget.5344.

10.

MDM4 SNP34091 (rs4245739) and its effect on breast-, colon-, lung-, and prostate cancer risk.

Gansmo LB, Romundstad P, Birkeland E, Hveem K, Vatten L, Knappskog S, Lønning PE.

Cancer Med. 2015 Dec;4(12):1901-7. doi: 10.1002/cam4.555. Epub 2015 Oct 16.

11.

Norwegian PUQE (Pregnancy-Unique Quantification of Emesis and nausea) identifies patients with hyperemesis gravidarum and poor nutritional intake: a prospective cohort validation study.

Birkeland E, Stokke G, Tangvik RJ, Torkildsen EA, Boateng J, Wollen AL, Albrechtsen S, Flaatten H, Trovik J.

PLoS One. 2015 Apr 1;10(4):e0119962. doi: 10.1371/journal.pone.0119962. eCollection 2015.

12.

Hyperemesis gravidarum, nutritional treatment by nasogastric tube feeding: a 10-year retrospective cohort study.

Stokke G, Gjelsvik BL, Flaatten KT, Birkeland E, Flaatten H, Trovik J.

Acta Obstet Gynecol Scand. 2015 Apr;94(4):359-67. doi: 10.1111/aogs.12578. Epub 2015 Feb 17.

PMID:
25581215
13.

Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelial-mesenchymal transition and PI3K alterations.

Wik E, Trovik J, Kusonmano K, Birkeland E, Raeder MB, Pashtan I, Hoivik EA, Krakstad C, Werner HM, Holst F, Mjøs S, Halle MK, Mannelqvist M, Mauland KK, Oyan AM, Stefansson IM, Petersen K, Simon R, Cherniack AD, Meyerson M, Kalland KH, Akslen LA, Salvesen HB.

Gynecol Oncol. 2014 Sep;134(3):599-606. doi: 10.1016/j.ygyno.2014.06.026. Epub 2014 Jul 1.

PMID:
24995579
14.

Stathmin protein level, a potential predictive marker for taxane treatment response in endometrial cancer.

Werner HM, Trovik J, Halle MK, Wik E, Akslen LA, Birkeland E, Bredholt T, Tangen IL, Krakstad C, Salvesen HB.

PLoS One. 2014 Feb 25;9(2):e90141. doi: 10.1371/journal.pone.0090141. eCollection 2014.

15.

Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma.

Birkeland E, Busch C, Berge EO, Geisler J, Jönsson G, Lillehaug JR, Knappskog S, Lønning PE.

Clin Exp Metastasis. 2013 Oct;30(7):867-76. doi: 10.1007/s10585-013-9587-4. Epub 2013 May 15.

16.

High phospho-Stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition.

Wik E, Birkeland E, Trovik J, Werner HM, Hoivik EA, Mjos S, Krakstad C, Kusonmano K, Mauland K, Stefansson IM, Holst F, Petersen K, Oyan AM, Simon R, Kalland KH, Ricketts W, Akslen LA, Salvesen HB.

Clin Cancer Res. 2013 May 1;19(9):2331-41. doi: 10.1158/1078-0432.CCR-12-3413. Epub 2013 Mar 28.

17.

Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers.

Raeder MB, Birkeland E, Trovik J, Krakstad C, Shehata S, Schumacher S, Zack TI, Krohn A, Werner HM, Moody SE, Wik E, Stefansson IM, Holst F, Oyan AM, Tamayo P, Mesirov JP, Kalland KH, Akslen LA, Simon R, Beroukhim R, Salvesen HB.

PLoS One. 2013;8(2):e54873. doi: 10.1371/journal.pone.0054873. Epub 2013 Feb 5.

18.

Lack of estrogen receptor-α is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma.

Wik E, Ræder MB, Krakstad C, Trovik J, Birkeland E, Hoivik EA, Mjos S, Werner HM, Mannelqvist M, Stefansson IM, Oyan AM, Kalland KH, Akslen LA, Salvesen HB.

Clin Cancer Res. 2013 Mar 1;19(5):1094-105. doi: 10.1158/1078-0432.CCR-12-3039. Epub 2013 Jan 14.

19.

High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutated.

Krakstad C, Birkeland E, Seidel D, Kusonmano K, Petersen K, Mjøs S, Hoivik EA, Wik E, Halle MK, Øyan AM, Kalland KH, Werner HM, Trovik J, Salvesen H.

PLoS One. 2012;7(12):e52795. doi: 10.1371/journal.pone.0052795. Epub 2012 Dec 27.

20.

KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer.

Birkeland E, Wik E, Mjøs S, Hoivik EA, Trovik J, Werner HM, Kusonmano K, Petersen K, Raeder MB, Holst F, Øyan AM, Kalland KH, Akslen LA, Simon R, Krakstad C, Salvesen HB.

Br J Cancer. 2012 Dec 4;107(12):1997-2004. doi: 10.1038/bjc.2012.477. Epub 2012 Oct 25.

21.

ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas.

Werner HM, Berg A, Wik E, Birkeland E, Krakstad C, Kusonmano K, Petersen K, Kalland KH, Oyan AM, Akslen LA, Trovik J, Salvesen HB.

Mod Pathol. 2013 Mar;26(3):428-34. doi: 10.1038/modpathol.2012.174. Epub 2012 Oct 19.

22.

Loss of GPER identifies new targets for therapy among a subgroup of ERα-positive endometrial cancer patients with poor outcome.

Krakstad C, Trovik J, Wik E, Engelsen IB, Werner HM, Birkeland E, Raeder MB, Øyan AM, Stefansson IM, Kalland KH, Akslen LA, Salvesen HB.

Br J Cancer. 2012 May 8;106(10):1682-8. doi: 10.1038/bjc.2012.91. Epub 2012 Mar 13.

23.

Stratification based on high tumour cell content in fresh frozen tissue promotes selection of aggressive endometrial carcinomas.

Halle MK, Werner HM, Krakstad C, Birkeland E, Wik E, Trovik J, Salvesen HB.

Histopathology. 2012 Feb;60(3):516-9. doi: 10.1111/j.1365-2559.2011.04057.x. Epub 2011 Dec 14. No abstract available.

PMID:
22168220
24.

[An agreement on insurance in medical practice].

Birkeland E.

Tidsskr Nor Laegeforen. 1995 May 20;115(13):1661. Norwegian. No abstract available.

PMID:
7778090
25.

[Reversal of sick-leave certificates issued by physicians].

Birkeland E, Lund I.

Tidsskr Nor Laegeforen. 1992 Jan 20;112(2):232. Norwegian. No abstract available.

PMID:
1566260

Supplemental Content

Loading ...
Support Center